You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBromazepam
Accession NumberDB01558
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionOne of the benzodiazepines that is used in the treatment of anxiety disorders. [PubChem] It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepines.
Structure
Thumb
Synonyms
Bromazepamum
Lectopam
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-bromazepam 1.5mg TabletsTablet1.5 mgOralAltimed Pharma Inc.1996-12-312005-05-27Canada
Alti-bromazepam 3mg TabletsTablet3 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-bromazepam 6mg TabletsTablet6 mgOralAltimed Pharma Inc.1996-12-312005-05-27Canada
Bromazepam-1.5 - Tab 1.5mgTablet1.5 mgOralPro Doc Limitee1997-05-202010-07-13Canada
Bromazepam-3 - Tab 3mgTablet3 mgOralPro Doc Limitee1996-12-04Not applicableCanada
Bromazepam-6 - Tab 6mgTablet6 mgOralPro Doc Limitee1996-12-04Not applicableCanada
Gen-bromazepam - Tab 3mgTablet3 mgOralGenpharm Ulc1995-12-312010-08-04Canada
Gen-bromazepam - Tab 6mgTablet6 mgOralGenpharm Ulc1995-12-312010-08-04Canada
Lectopam Tab 1.5mgTablet1.5 mgOralHoffmann La Roche Limited1986-12-312006-07-25Canada
Lectopam Tab 3mgTablet3 mgOralHoffmann La Roche Limited1981-12-31Not applicableCanada
Lectopam Tab 6mgTablet6 mgOralHoffmann La Roche Limited1981-12-31Not applicableCanada
Mylan-bromazepamTablet1.5 mgOralMylan Pharmaceuticals Ulc1995-12-312012-10-19Canada
Nu-bromazepam - Tab 1.5mgTablet1.5 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Nu-bromazepam - Tab 3mgTablet3 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Nu-bromazepam - Tab 6mgTablet6 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Penta-bromazepam TabletsTablet3 mgOralPentapharm Ltd.1999-07-132004-07-30Canada
Penta-bromazepam TabletsTablet6 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Riva-bromazepam 3 mgTablet3 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-bromazepam 6 mgTablet6 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Teva-bromazepamTablet3 mgOralTeva Canada Limited1997-03-03Not applicableCanada
Teva-bromazepamTablet6 mgOralTeva Canada Limited1997-03-03Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-bromazepam - Tab 1.5mgTablet1.5 mgOralApotex Inc1995-12-31Not applicableCanada
Apo-bromazepam - Tab 3mgTablet3 mgOralApotex Inc1995-12-31Not applicableCanada
Apo-bromazepam - Tab 6mgTablet6 mgOralApotex Inc1995-12-31Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CalmepamNot Available
CreosedinNot Available
DurazanilNot Available
LectopamNot Available
LekotamNot Available
LexaurinNot Available
LexiliumNot Available
LexomilNot Available
LexotanNot Available
NormocNot Available
UltramidolNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIX015L14V0O
CAS number1812-30-2
WeightAverage: 316.153
Monoisotopic: 315.000724604
Chemical FormulaC14H10BrN3O
InChI KeyVMIYHDSEFNYJSL-UHFFFAOYSA-N
InChI
InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)
IUPAC Name
7-bromo-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1
Pharmacology
IndicationFor the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.
Structured Indications
PharmacodynamicsBromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam shares with other benzodiazepines the risk of abuse, misuse, psychological and/or physical dependence. According to many psychiatric experts Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.
Mechanism of actionBromazepam binds to the GABA receptor GABAA, causing a conformational change and increasing inhibitory effects of GABA. Other neurotransmitters are not influenced.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinyes
potentiator
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinyes
potentiator
HumanP34903 details
Gamma-aminobutyric acid receptor subunit alpha-4Proteinyes
potentiator
HumanP48169 details
Gamma-aminobutyric acid receptor subunit alpha-5Proteinyes
potentiator
HumanP31644 details
Gamma-aminobutyric acid receptor subunit alpha-6Proteinyes
potentiator
HumanQ16445 details
Gamma-aminobutyric acid receptor subunit beta-1Proteinyes
potentiator
HumanP18505 details
Gamma-aminobutyric acid receptor subunit beta-2Proteinyes
potentiator
HumanP47870 details
Gamma-aminobutyric acid receptor subunit beta-3Proteinyes
potentiator
HumanP28472 details
Gamma-aminobutyric acid receptor subunit gamma-1Proteinyes
potentiator
HumanQ8N1C3 details
Gamma-aminobutyric acid receptor subunit gamma-2Proteinyes
potentiator
HumanP18507 details
Gamma-aminobutyric acid receptor subunit gamma-3Proteinyes
potentiator
HumanQ99928 details
Gamma-aminobutyric acid receptor subunit deltaProteinyes
potentiator
HumanO14764 details
Gamma-aminobutyric acid receptor subunit epsilonProteinyes
potentiator
HumanP78334 details
Gamma-aminobutyric acid receptor subunit piProteinyes
potentiator
HumanO00591 details
Gamma-aminobutyric acid receptor subunit rho-1Proteinyes
potentiator
HumanP24046 details
Gamma-aminobutyric acid receptor subunit rho-2Proteinyes
potentiator
HumanP28476 details
Gamma-aminobutyric acid receptor subunit rho-3Proteinyes
potentiator
HumanA8MPY1 details
Gamma-aminobutyric acid receptor subunit thetaProteinyes
potentiator
HumanQ9UN88 details
Related Articles
AbsorptionBioavailability is 84% following oral administration. The time to peak plasma level is 1 - 4 hours. Bromazepam is generally well absorbed after oral administration.
Volume of distribution

1.56 L/kg

Protein binding70%
Metabolism

Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes). One of the main metabolites is 3-hydroxybromazepam. It is pharmacologically active and the half life is similar to that of the parent compound.

Route of eliminationUrine (69%), as metabolites
Half life10-20 hours
Clearance

0.82 mL/min/kg.

ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Bromazepam is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Bromazepam is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Bromazepam can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Bromazepam is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Bromazepam.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Bromazepam.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Bromazepam.Approved, Illicit, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Ambroxol acefyllinate.Experimental
AminophyllineThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Bromazepam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Bromazepam.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amperozide.Experimental
AprepitantThe serum concentration of Bromazepam can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromazepam.Approved, Investigational
ArmodafinilThe metabolism of Bromazepam can be decreased when combined with Armodafinil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Asenapine.Approved
AtazanavirThe metabolism of Bromazepam can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Bromazepam can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Azaperone.Vet Approved
AzelastineBromazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Azelastine.Approved
AzithromycinThe metabolism of Bromazepam can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Bromazepam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Bromazepam.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Bromazepam.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Bromazepam is combined with Benzyl alcohol.Approved
BexaroteneThe serum concentration of Bromazepam can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Bromazepam can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Bromazepam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bromazepam can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved
BrompheniramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Bromazepam.Approved, Investigational
BuprenorphineBromazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Bromazepam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Bromazepam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Bromazepam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Bromazepam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Bromazepam.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bromazepam.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Bromazepam can be decreased when combined with Caffeine.Approved
CarbamazepineThe metabolism of Bromazepam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Bromazepam.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Bromazepam can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Bromazepam can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bromazepam.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Bromazepam.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Bromazepam.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Bromazepam.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Bromazepam.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Bromazepam can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Bromazepam can be increased when it is combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Bromazepam.Approved, Vet Approved
CitalopramThe metabolism of Bromazepam can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Bromazepam can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Bromazepam can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Bromazepam is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Bromazepam.Approved, Illicit
ClotrimazoleThe metabolism of Bromazepam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clozapine.Approved
CobicistatThe metabolism of Bromazepam can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Bromazepam.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Bromazepam.Approved, Illicit
ConivaptanThe serum concentration of Bromazepam can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Bromazepam can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromazepam.Approved
CyclosporineThe metabolism of Bromazepam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Bromazepam can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Bromazepam can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Bromazepam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Bromazepam can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Bromazepam can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Bromazepam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Bromazepam can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Bromazepam is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Bromazepam.Approved
DesipramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Bromazepam can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bromazepam.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Bromazepam.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bromazepam.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Bromazepam.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Bromazepam.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bromazepam.Approved, Illicit
DihydroergotamineThe metabolism of Bromazepam can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Bromazepam.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Bromazepam can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bromazepam.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bromazepam.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Doxepin.Approved
DoxycyclineThe metabolism of Bromazepam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Bromazepam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit
DronedaroneThe metabolism of Bromazepam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Bromazepam.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Bromazepam.Approved
DyphyllineThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Dyphylline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Bromazepam.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Bromazepam is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Bromazepam can be decreased when it is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Bromazepam.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Bromazepam is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Bromazepam can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Bromazepam can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Bromazepam is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Bromazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Bromazepam can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Bromazepam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Bromazepam.Approved
EthanolBromazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bromazepam.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Bromazepam.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Bromazepam.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Bromazepam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Bromazepam.Illicit, Vet Approved
EtravirineThe serum concentration of Bromazepam can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Bromazepam.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bromazepam.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Flibanserin.Approved
FluconazoleThe metabolism of Bromazepam can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Bromazepam.Approved, Illicit
FluoxetineThe metabolism of Bromazepam can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Bromazepam.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Bromazepam.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Bromazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluticasone Propionate.Approved
FluvoxamineThe serum concentration of Bromazepam can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Bromazepam can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Bromazepam can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Bromazepam.Approved
FospropofolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Bromazepam can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bromazepam.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Bromazepam is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Bromazepam.Approved, Illicit
GemfibrozilThe metabolism of Bromazepam can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Bromazepam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Bromazepam.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Bromazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Bromazepam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Bromazepam.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Bromazepam.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Bromazepam.Approved
HyaluronidaseThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneBromazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromazepam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved
IdelalisibThe serum concentration of Bromazepam can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Iloperidone.Approved
ImatinibThe metabolism of Bromazepam can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Bromazepam can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Bromazepam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Bromazepam.Approved, Vet Approved
IsoniazidThe metabolism of Bromazepam can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Bromazepam can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Bromazepam can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Bromazepam can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Bromazepam.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Bromazepam can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Bromazepam.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Bromazepam.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bromazepam.Approved
LidocaineThe metabolism of Bromazepam can be decreased when combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Bromazepam.Approved
LofentanilThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lofentanil.Illicit
LopinavirThe metabolism of Bromazepam can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Bromazepam.Approved
LovastatinThe metabolism of Bromazepam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Bromazepam.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Bromazepam is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Bromazepam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Bromazepam can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Bromazepam.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Bromazepam.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Bromazepam.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Bromazepam.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Metaxalone.Approved
MethadoneBromazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Bromazepam.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Bromazepam.Approved
MethotrimeprazineBromazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Bromazepam.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Bromazepam.Approved
MetyrosineBromazepam may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Bromazepam can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Bromazepam.Approved, Illicit
MifepristoneThe serum concentration of Bromazepam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Bromazepam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Investigational
MirtazapineBromazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Bromazepam can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Bromazepam can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Bromazepam can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Bromazepam.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Investigational
NafcillinThe serum concentration of Bromazepam can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bromazepam.Approved
NefazodoneThe metabolism of Bromazepam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Bromazepam can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Bromazepam can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Bromazepam can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Bromazepam can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Bromazepam can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Bromazepam.Approved, Investigational
OlaparibThe metabolism of Bromazepam can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Bromazepam can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Bromazepam.Approved
OpiumThe risk or severity of adverse effects can be increased when Bromazepam is combined with Opium.Approved, Illicit
OrphenadrineBromazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Bromazepam is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Bromazepam can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Bromazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Bromazepam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Bromazepam.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bromazepam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bromazepam.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Bromazepam can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Bromazepam.Approved
PantoprazoleThe metabolism of Bromazepam can be decreased when combined with Pantoprazole.Approved
ParaldehydeBromazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Bromazepam can be increased when it is combined with Peginterferon alfa-2b.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bromazepam.Approved, Vet Approved
PentobarbitalThe metabolism of Bromazepam can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved
PerazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Bromazepam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Bromazepam.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bromazepam.Approved
PhenobarbitalThe metabolism of Bromazepam can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Bromazepam.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Bromazepam.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Bromazepam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleBromazepam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Bromazepam.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Bromazepam.Approved
PrimidoneThe metabolism of Bromazepam can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Bromazepam.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bromazepam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Bromazepam.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Bromazepam.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Bromazepam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Bromazepam is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Bromazepam.Approved
RacloprideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Bromazepam can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bromazepam.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Bromazepam.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Bromazepam.Approved
RifabutinThe metabolism of Bromazepam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Bromazepam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Bromazepam can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Bromazepam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ritanserin.Investigational
RitonavirThe metabolism of Bromazepam can be decreased when combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Romifidine.Vet Approved
RopiniroleBromazepam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Bromazepam.Approved
RotigotineBromazepam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Bromazepam.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Bromazepam is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Bromazepam is combined with Sage 547.Investigational
SaquinavirThe metabolism of Bromazepam can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Bromazepam.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Bromazepam is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Bromazepam can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Bromazepam.Approved, Vet Approved
SildenafilThe metabolism of Bromazepam can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Bromazepam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Bromazepam can be increased when it is combined with Simeprevir.Approved
Sodium oxybateBromazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
St. John's WortThe serum concentration of Bromazepam can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Bromazepam can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bromazepam.Approved, Investigational
SulfisoxazoleThe metabolism of Bromazepam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Bromazepam.Approved
SuvorexantBromazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tasimelteon.Approved
TeduglutideThe serum concentration of Bromazepam can be increased when it is combined with Teduglutide.Approved
TelaprevirThe metabolism of Bromazepam can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Bromazepam can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Bromazepam.Approved
TenofovirThe metabolism of Bromazepam can be decreased when combined with Tenofovir.Approved, Investigational
TeriflunomideThe serum concentration of Bromazepam can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrodotoxin.Investigational
ThalidomideBromazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Bromazepam.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Bromazepam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Bromazepam.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tiapride.Investigational
TiclopidineThe metabolism of Bromazepam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Bromazepam can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bromazepam.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bromazepam.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Bromazepam.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Bromazepam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Bromazepam.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Bromazepam.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Bromazepam is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Bromazepam.Approved, Investigational
VemurafenibThe serum concentration of Bromazepam can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Bromazepam can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Bromazepam can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Bromazepam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Bromazepam.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Bromazepam can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zolazepam.Vet Approved
ZolpidemBromazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Bromazepam.Approved
ZotepineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451 ]
  2. Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, Kuwatani K, Nakano S: The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur J Clin Pharmacol. 2003 Nov;59(8-9):615-9. Epub 2003 Sep 27. [PubMed:14517708 ]
  3. van Harten J: Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29 Suppl 1:1-9. [PubMed:8846617 ]
  4. Ochs HR, Greenblatt DJ, Friedman H, Burstein ES, Locniskar A, Harmatz JS, Shader RI: Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987 May;41(5):562-70. [PubMed:2882883 ]
External Links
ATC CodesN05BA08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9937
Blood Brain Barrier+0.9848
Caco-2 permeable+0.7571
P-glycoprotein substrateSubstrate0.5741
P-glycoprotein inhibitor INon-inhibitor0.7251
P-glycoprotein inhibitor IINon-inhibitor0.924
Renal organic cation transporterNon-inhibitor0.558
CYP450 2C9 substrateNon-substrate0.8385
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.7117
CYP450 1A2 substrateInhibitor0.9381
CYP450 2C9 inhibitorNon-inhibitor0.6329
CYP450 2D6 inhibitorNon-inhibitor0.8511
CYP450 2C19 inhibitorNon-inhibitor0.5719
CYP450 3A4 inhibitorNon-inhibitor0.7405
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6441
Ames testNon AMES toxic0.8607
CarcinogenicityNon-carcinogens0.8704
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.2416 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9974
hERG inhibition (predictor II)Non-inhibitor0.7977
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral1.5 mg
TabletOral3 mg
TabletOral6 mg
Prices
Unit descriptionCostUnit
Lectopam 6 mg Tablet0.25USD tablet
Lectopam 3 mg Tablet0.17USD tablet
Apo-Bromazepam 6 mg Tablet0.13USD tablet
Gen-Bromazepam 6 mg Tablet0.13USD tablet
Novo-Bromazepam 6 mg Tablet0.13USD tablet
Apo-Bromazepam 3 mg Tablet0.09USD tablet
Gen-Bromazepam 3 mg Tablet0.09USD tablet
Novo-Bromazepam 3 mg Tablet0.09USD tablet
Apo-Bromazepam 1.5 mg Tablet0.07USD tablet
Gen-Bromazepam 1.5 mg Tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.05SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0399 mg/mLALOGPS
logP2.09ALOGPS
logP2.54ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.24ChemAxon
pKa (Strongest Basic)2.68ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.35 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity76.99 m3·mol-1ChemAxon
Polarizability28.11 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00n0-9463000000-abe7fdab778f08fe18c4View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Bromobenzene
  • Benzenoid
  • Pyridine
  • Aryl halide
  • Aryl bromide
  • Heteroaromatic compound
  • Secondary carboxylic acid amide
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transmembrane signaling receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRQ
Uniprot ID:
Q9UN88
Molecular Weight:
72020.875 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:10 / Updated on August 17, 2016 12:23